Editas Medicine Inc (EDIT) COO Alexandra Glucksmann Sells 1,000 Shares

Editas Medicine Inc (NASDAQ:EDIT) COO Alexandra Glucksmann sold 1,000 shares of the business’s stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $26.41, for a total transaction of $26,410.00. Following the transaction, the chief operating officer now directly owns 118,788 shares of the company’s stock, valued at approximately $3,137,191.08. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Alexandra Glucksmann also recently made the following trade(s):

  • On Wednesday, February 15th, Alexandra Glucksmann sold 6,000 shares of Editas Medicine stock. The stock was sold at an average price of $20.58, for a total transaction of $123,480.00.

Editas Medicine Inc (NASDAQ:EDIT) traded up 0.49% on Monday, hitting $22.41. 1,434,599 shares of the stock traded hands. Editas Medicine Inc has a 52 week low of $12.43 and a 52 week high of $43.50. The firm’s 50 day moving average is $21.84 and its 200 day moving average is $17.26. The stock’s market cap is $803.17 million.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings data on Friday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by $0.48. Editas Medicine had a negative return on equity of 59.22% and a negative net margin of 1,184.46%. During the same quarter in the prior year, the company posted ($4.05) EPS. Equities analysts anticipate that Editas Medicine Inc will post ($2.85) earnings per share for the current year.

Insider Buying and Selling by Quarter for Editas Medicine (NASDAQ:EDIT)

Your IP Address:

Large investors have recently modified their holdings of the company. EcoR1 Capital LLC bought a new stake in shares of Editas Medicine during the fourth quarter valued at about $10,172,000. Foresite Capital Management III LLC bought a new stake in shares of Editas Medicine during the fourth quarter valued at about $4,462,000. State Street Corp increased its stake in shares of Editas Medicine by 2.4% in the fourth quarter. State Street Corp now owns 105,167 shares of the company’s stock valued at $1,708,000 after buying an additional 2,476 shares in the last quarter. Norges Bank bought a new stake in shares of Editas Medicine during the fourth quarter valued at about $1,479,000. Finally, Highland Capital Management LP bought a new stake in shares of Editas Medicine during the fourth quarter valued at about $1,460,000. 60.89% of the stock is owned by institutional investors.

A number of research firms have weighed in on EDIT. Vetr raised shares of Editas Medicine from a “buy” rating to a “strong-buy” rating and set a $27.14 target price for the company in a research report on Monday. Jefferies Group LLC set a $35.00 target price on shares of Editas Medicine and gave the stock a “buy” rating in a research report on Monday, December 12th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Editas Medicine in a research report on Sunday, February 19th. Zacks Investment Research lowered shares of Editas Medicine from a “hold” rating to a “sell” rating in a research report on Friday, March 10th. Finally, Cowen and Company restated a “buy” rating on shares of Editas Medicine in a report on Wednesday, March 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $27.79.

About Editas Medicine

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

5 Day Chart for NASDAQ:EDIT

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2024166/editas-medicine-inc-edit-coo-alexandra-glucksmann-sells-1000-shares.html

Receive News & Ratings for Editas Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.